JFA
RXRX icon

JNBA Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

JNBA Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569 Hold
155
– – ﹤0.01% 801
2026
Q1 		$476 Hold
155
– – ﹤0.01% 800
2025
Q4 		$634 Hold
155
– – ﹤0.01% 767
2025
Q3 		$757 Buy
+155
New +$814 ﹤0.01% 628
2025
Q2 		– Sell
-2,450
Closed -$13K – 686
2025
Q1 		$13K Buy
+2,450
New +$17.9K ﹤0.01% 429

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JNBA Financial Advisors's RXRX Position: Q2 2026 in Review

JNBA Financial Advisors held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 155 shares worth $569. The position accounts for ﹤0.01% of the portfolio, ranked #801.

JNBA Financial Advisors first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $13K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • JNBA Financial Advisors held 155 shares of Recursion Pharmaceuticals worth $569 as of Q2 2026.
  • JNBA Financial Advisors left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of JNBA Financial Advisors's portfolio in Q2 2026, its #801 holding.
  • JNBA Financial Advisors first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • JNBA Financial Advisors's Recursion Pharmaceuticals position peaked at $13K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on JNBA Financial Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.